Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 2,446

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

Thompson, Ian M., Pauler, Donna K., Goodman, Phyllis J., Tangen, Catherine M., Lucia, M. Scott, Parnes, Howard L., Minasian, Lori M., Ford, Leslie G., Lippman, Scott M., Crawford, E. David, Crowley, John J., Coltman, Charles A. · 2004 · New England Journal of Medicine

Abstract

BACKGROUND: The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less. METHODS: Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years. RESULTS: Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa031918

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 16

  1. Wang MC, 1979, Invest Urol, 17, 159
  2. Brawley OW, 1998, Semin Urol Oncol, 16, 187
  3. 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B · DOI
  4. Thompson IM, 2003, World J Urol, 21, 28, 10.1007/s00345-002-0315-y · doi:10.1007/s00345-002-0315-y
  5. 10.1111/j.1464-410X.1987.tb09137.x · doi:10.1111/j.1464-410x.1987.tb09137.x
  6. Kuriyama M, 1980, Cancer Res, 40, 4658
  7. Liedtke RJ, 1984, Clin Chem, 30, 649, 10.1093/clinchem/30.5.649 · doi:10.1093/clinchem/30.5.649
  8. Yang N, 1984, Clin Chem, 30, 1057
  9. 10.1016/0090-4295(86)90146-9 · doi:10.1016/0090-4295(86)90146-9
  10. Kuriyama M, 1982, J Natl Cancer Inst, 68, 99
  11. Thompson IM, 1984, J Urol, 132, 690, 10.1016/S0022-5347(17)49828-4 · doi:10.1016/s0022-5347(17)49828-4
  12. Ruebush TK II, 1979, J Urol, 122, 492, 10.1016/S0022-5347(17)56477-0 · doi:10.1016/s0022-5347(17)56477-0
  13. 10.1016/S0022-5347(01)63951-X · doi:10.1016/s0022-5347(01)63951-x
  14. 10.1016/S0090-4295(96)00091-X · doi:10.1016/s0090-4295(96)00091-x
  15. 10.1093/jnci/90.16.1230 · doi:10.1093/jnci/90.16.1230
  16. 10.1016/S0140-6736(00)02269-8 · doi:10.1016/s0140-6736(00)02269-8

Cited by

See all 2,446

Metadata

Authors
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., & Coltman, C. A.
Venue
New England Journal of Medicine
Published
2004-05-27
Volume
350
Issue
22
Pages
2239-2246
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2140687262
Cited by
2,446
References
16
FWCI
118.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.